Innovate UK grants £4m to four companies to evaluate biomarkers for dementia
The progressive neurodegenerative disease affects more than 55 million people globally
Read More
Tag: Novo Nordisk
Novo Nordisk to open new AI hub in UK for drug discovery
The new hub will be located in the King’s Cross Knowledge Quarter, London
Read More
Positive opinion for Novo Nordisk’s Sogroya
Therapy has been developed for use among children and adolescents with growth hormone deficiency
Read More
Novo Nordisk weight-loss drug available across NHS
NICE has recommended the use of semaglutide alongside a reduced-calorie diet and exercise
Read More
Novo Nordisk’s icodec therapy delivers positive data
Data shows participants achieved greater treatment satisfaction when switching to icodec
Read More
Novo Nordisk release results from haemophilia treatment study
Data shows a significant reduction in treated spontaneous and traumatic bleeds among haemophilia patients
Read More
Novo Nordisk to build on heritage in rare blood disorders
New data will be released at the International Society on Thrombosis and Haemostasis Congress
Read More
Novo Nordisk’s weight loss drug semaglutide found to improve wellbeing
New results from a Phase IIIa study demonstrate benefits of drug for people with obesity ‘beyond weight loss’
Read More
Novo Nordisk plans study of oral semaglutide in obesity
Study will include approximately 1,000 people with obesity or overweight with comorbidities
Read More
FDA refuses Novo Nordisk’s once-weekly semaglutide
Company had been aiming for approval in type 2 diabetes
Read More
Novo Nordisk invests in facility expansion at production site in Denmark
Production site in Måløv, Denmark manufactures products for oral diabetes treatment Rybelsus
Read More
Novo Nordisk’s semaglutide cuts body weight in large-scale trial
Participants lost on average 14.9% of their baseline body weight
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
